How The Kura Oncology (KURA) Narrative Is Shifting With Komzifti Launch And New Analyst Targets [Yahoo! Finance]
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: Yahoo! Finance
Kura Oncology's fair value estimate has been adjusted from US$32.27 to US$31.08, a small move that still reflects detailed work behind the numbers. Analysts are weighing upbeat signals around Komzifti's early launch against more cautious takes tied to price target cuts to levels such as US$15, US$30, and US$36, which you can see in the mix of updated models. Read on to see how these shifting targets, and the reasoning behind them, can help you track the evolving story around Kura. Stay updated as the Fair Value for Kura Oncology shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Kura Oncology. What Wall Street Has Been Saying ?? Bullish Takeaways BofA lifted its Kura Oncology price target to US$30 from US$29 after Q4 updates, citing feedback that Komzifti's safety, convenience, and potential for combinations are resonating with the market. Wedbush, while trimming its target to US$36 from US$38, highlight
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell Carcinoma Transcript [Seeking Alpha]Seeking Alpha
- Kura Oncology Shares Surge Following Positive Kidney Cancer Trial Data [TheStreet.com]TheStreet.com
- Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With CabozantinibGlobeNewswire
- Kura Oncology (KURA) was upgraded by Lake Street Capital to "strong-buy".MarketBeat
- Kura Oncology (KURA) is now covered by Lake Street Capital. They set a "buy" rating on the stock.MarketBeat
KURA
Earnings
- 3/5/26 - Miss
KURA
Sec Filings
- 4/10/26 - Form ARS
- 4/10/26 - Form DEFA14A
- 4/10/26 - Form DEF
- KURA's page on the SEC website